Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Jade Biosciences Inc JBIO

Healthcare Biotechnology
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage... see more

Current News (NDAQ:JBIO)

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

GlobeNewswire 15 hours ago

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

GlobeNewswire March 6, 2026

Jade Biosciences to Participate in Upcoming Conferences

GlobeNewswire February 11, 2026

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

Jade Biosciences Announces $45 Million Private Placement

GlobeNewswire December 15, 2025

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2025

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

GlobeNewswire November 8, 2025

Jade Biosciences to Participate in Upcoming Conferences

GlobeNewswire November 3, 2025

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

GlobeNewswire October 17, 2025
View More News ››

Opinion & Analysis (NDAQ:JBIO)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:JBIO)

Be the first to post on this bullboard.

New Pacific Metals Corp

New Pacific Metals Corp

New Pacific Metals Corp., together with its subsidiaries, engages in the exploration and development of mineral properties in ...
View More »

Podcasts